Quantitative Aspects of Non-targeted Analysis for Organic Extractables/Leachables; Insights Secured by Considering the FDA CLAP List Compounds

Substances released from a drug product’s manufacturing, packaging, and delivery system are termed leachables. Medical device leachables are released during their clinical use. Packaged drug products and medical devices are profiled for leachables (and/or extractables as probable leachables) by screening the drug product or extracts via non-targeted analysis (NTA) employing chromatography coupled with mass spectrometric detection. A leachable’s concentration is important as concentration is establishes a patient’s exposure to leachables during the clinical use of a drug product or medical device. Two issues are relevant when quantifying extractables or leachables (E/L) during NTA: when is quantitation necessary, and how is quantitation accomplished? Quantitation for toxicological safety risk assessment is necessary if the E/L is present at a level that exceeds the Analytical Evaluation Threshold (AET). To address compound-to-compound variation in analytical response, the AET is lowered via an Uncertainty Factor (UF). Estimated concentrations for identified E/Ls are accurate if either a reference standard is available for the E/L or the E/L can be linked to a surrogate reference compound. However, these approaches are not applicable to unidentified E/Ls or when reference compounds are unavailable. The means for calculating the UF and the use of a universal quantitation surrogate, specifically the median relative response factor (RRF) of a data set of compounds, to estimate the concentration of unidentified E/L are considered herein. Using the FDA CLAP list as a reference, this manuscript concludes that the proper calculation of the UF involves the median RRF and the RRF at the 16% percentile. Furthermore, this manuscript establishes that methods coupling liquid chromatography with mass spectrometric detection (electrospray ionization, ESI) are inaccurate when quantifying unidentified E/Ls given the large variation in RRF values. However, as RRF values for GC/MS are less variable, concentrations estimated for unidentified E/Ls using RRFmedian can be accurate and protective.

Authors

Institutions

Publication Details

Journal
PDA Journal of Pharmaceutical Science and Technology
Published
2026-09-12
DOI
https://doi.org/10.5731/pdajpst.2026-000062.1
Primary Topic
Effects and risks of endocrine disrupting chemicals
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Quantitative Aspects of Non-targeted Analysis for Organic Extractables/Leachables; Insights Secured by Considering the FDA CLAP List Compounds

Piet Christiaens, Jan Baeten, Dennis Jenke, Philippe Verlinde
PDA Journal of Pharmaceutical Science and Technology
Effects and risks of endocrine disrupting chemicals
article

Quantitative Aspects of Non-targeted Analysis for Organic Extractables/Leachables; Insights Secured by Considering the FDA CLAP List Compounds

Piet Christiaens, Jan Baeten, Dennis Jenke, Philippe Verlinde
article en

Abstract

No abstract available for this paper.

PDA Journal of Pharmaceutical Science and Technology
Scientific Solutions (United States) (US), Nelson Engineering (United States) (US)
Openalex Percentile: Top 12%
Effects and risks of endocrine disrupting chemicals
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.